IDS join Pan-European APPROACH consortium, to provide improved drug development and prognosis tools for osteoarthritis patients worldwide.

Family playing tug-of-war on a beach

Immunodiagnostic Systems Limited is a leading in vitro diagnostic solutions provider to the clinical and research laboratory markets.  We are committed to providing highly accurate and reproducible immunoassays and offer the most promising markers according to BIPED (Burden of disease, Investigative, Prognostic, Efficacy of intervention and Diagnostic) criteria to analyse cartilage related events in body fluids or tissues1.

IDS have joined forces in the pan-European APPROACH (Applied Public-Private Research enabling Osteo Arthritis Clinical Headway) consortium of 24 partners comprising of pharmaceutical companies, biotech companies, academic institutions, non-profit organisations, small and medium enterprises and public bodies.  The APPROACH consortium will combine biomedical data from more than 10,000 patients and controls from nine existing cohorts into a unified bioinformatics platform.  Ultimately, this platform will consequently lead to improved drug development and diagnostic / prognostic tools that allowing osteoarthritis patients to receive highlight personalised treatment2.

Osteoarthritis is a degenerative joint disease, which mainly affects the articular cartilage. It is associated with ageing and will most likely affect the joints that have been continually stressed throughout the years including the knees, hips, fingers, and lower spine region.  Osteoarthritis is already one of the ten most disabling diseases in developed countries.  Worldwide estimates are that 9.6% of men and 18.0% of women aged over 60 years have symptomatic osteoarthritis. 80% of those with osteoarthritis will have limitations in movement and 25% cannot perform their major daily activities of life3.

  1. Rousseau JC, Delmas PD. Biological markers in osteoarthritis. Nat Clin Pract Rheumatol. 2007 Jun; 3(6):346-56.
  1. Wolf AD, Pfleger B. Burden of major musculoskeletal conditions. Policy and Practice.  Bulletin of the World Health Organization 2003, 81(9):646-656.